Elesta S.r.l. was founded in 2005 as a joint-venture by Esaote S.p.A. (global leader in the production of ultrasound devices, no longer part of the joint-venture) and El.En. S.p.A. (world leader in the production of laser systems, today majority shareholder of Elesta S.r.l.) with the purpose of developing, producing and selling innovative hi-tech medical devices for micro-invasive therapeutic applications. The main product of Elesta is EchoLaser: the first and unique integrated Laser-Ultrasound system that allows diagnosis and micro-invasive treatment of benign and malignant lesions. EchoLaser uses the laser light transmitted by up to four extremely thin optical
Core EchoLaser Therapy applications are:
ModìLite – lesions of the neck, such as benign thyroid nodules and metastatic lymph nodes.
SoracteLite – urinary system disorders like Benign Prostatic Hyperplasia (BPH), producing a progressive reduction in the volume of the prostatic lobes and subsequent disappearance of the symptoms. SoracteLite is the first and only laser treatment for BPH through a trans-perineal approach (reducing complications of traditional trans-urethral approach)
Elesta is developing other EchoLaser Therapy applications on soft tissues lesions such as breast, pancreas
Develop and market high-tech devices for the treatment of soft tissue lesions.
Our products aim to protect the health of patients by offering innovative therapeutic solutions that are as equally efficient as and less invasive than traditional surgical treatments.
One of the key features of our therapeutic approach is the rapid post-treatment recovery for patients, that also ensures enormous advantages in economic and socio-health terms.